NCT07090148View on ClinicalTrials.gov

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2030

Conditions
Prostate Cancer PatientsNon-castrate Prostate CancerRecurrent Prostate CancerOligometastatic Prostate Cancer (OMPC)
Interventions
BIOLOGICAL

pTVG-HP DNA vaccine

The vaccine will be injected into the outer side of the upper area of the arm in two adjacent sites, with 0.25 mL administered at each site.

DRUG

Anti-PD-1 monoclonal antibody

Nivolumab is a potent human immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Participants will receive two 10mg doses.

Trial Locations (1)

53705

University of Wisconsin - Madison, Madison

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Wisconsin, Madison

OTHER